Compare Abeona Therapeutics Inc (ABEO) vs SAP SE (SAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SAP SE — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while SAP SE trades at $157.66 (market cap $191.33B). The key difference: SAP SE is far larger — about 512.5× Abeona Therapeutics Inc's market cap, and SAP SE pays a 1.8% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SAP | |
|---|---|---|
Market Cap | $373.32M | $191.33B |
Sector | Health | Technology |
52-Week High | $7.23 | $311.93 |
52-Week Low | $4.17 | $148.06 |
Enterprise Value | $228.22M | $188.85B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SAP trades at $162.77, up 0.11% with recent earnings beats driving positive momentum. The stock shows strong fundamentals with 19.58% net margins and consistent revenue growth to $36.8B in 2025. Technical indicators are mixed with bearish moving averages but neutral oscillators, while analyst consensus remains bullish with a $228.50 price target representing 40% upside potential from current levels.
SAP presents a compelling investment case with robust profitability and strategic AI investments, though near-term technical weakness and competitive pressures from Oracle's AI spending create headwinds. The company's cloud transition progress and strong cash flow generation support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
